Surmodics
SRDX
SRDX was delisted on the 18th of November, 2025.
152 hedge funds and large institutions have $697M invested in Surmodics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 67 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
3% more funds holding
Funds holding: 147 → 152 (+5)
3% more capital invested
Capital invested by funds: $677M → $697M (+$19.7M)
0.37% more ownership
Funds ownership: 90.01% → 90.37% (+0.37%)
45% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 67
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $339K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.73M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.56M |
| 3 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$4.79M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$2.67M |
| 5 |
SG Americas Securities
New York
|
+$728K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.79M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.64M |
| 3 |
Millennium Management
New York
|
-$1.94M |
| 4 |
Renaissance Technologies
New York
|
-$1.64M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.24M |
SRDX Hedge Fund Activity: Q3 2021 in Review
152 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Surmodics (SRDX) for Q3 2021, worth a combined $697M — up 2.9% from $677M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SRDX positions and 10 closed out — a net gain of 6 holders — while 37 added to existing stakes and 67 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $5.73M. The largest seller was Goldman Sachs, cutting an estimated $2.79M.
- 152 institutional investors held Surmodics (SRDX) as of Q3 2021, up from 147 in Q2 2021.
- Funds reported $697M of Surmodics stock for Q3 2021, up 2.9% quarter-over-quarter.
- 16 funds opened new Surmodics positions in Q3 2021 and 10 closed out, a net change of +6 holders.
- The largest Surmodics buyer in Q3 2021 was Soleus Capital Management, an estimated $5.73M added.
- The largest Surmodics seller in Q3 2021 was Goldman Sachs, an estimated $2.79M sold.
Based on aggregated 13F filings for Q3 2021.